Beximco Pharmaceuticals Limited

Equities

BXPHARMA

BD0453BXPH04

Pharmaceuticals

End-of-day quote Dhaka S.E. 03:30:00 13/05/2024 am IST 5-day change 1st Jan Change
122.4 BDT -1.37% Intraday chart for Beximco Pharmaceuticals Limited -1.61% -16.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Beximco names Iqbal Ahmed as managing director AN
Beximco Pharmaceuticals to strengthen portfolio as interim profit up AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 30, 2023 CI
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Beximco MD steps down to join Bangladeshi cabinet AN
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board CI
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director CI
Beximco Pharmaceuticals Posts Higher Fiscal Q1 Profit, Revenue MT
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Beximco boosts revenue in local currency but profit falls AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended June 30, 2023 CI
Beximco working to fix deficiencies at manufacturing plant AN
Beximco Pharmaceuticals to Tackle Ophthalmic Manufacturing Unit Deficiencies After Malta Medicines Authority Audit MT
EARNINGS UPDATES: HC Slingsby profit falls, East Imperial loss narrows AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
TRADING UPDATES: Ferro-Alloy eyes revenue to drop below market view AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022 CI
UK shareholder meetings calendar - next 7 days AN
EARNINGS SUMMARY: Goodbody shifts away from Covid; Beximco profit down AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
IN BRIEF: Beximco Pharmaceuticals revenue up thanks to domestic sales AN
Chart Beximco Pharmaceuticals Limited
More charts
Beximco Pharmaceuticals Limited is a Bangladesh-based company which is a manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company is engaged in manufacturing and marketing of generic pharmaceutical formulation products covering a range of therapeutic categories. It offers products in different dosage forms, including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. Besides formulation products, the Company also manufactures APIs and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets. The subsidiaries of the Company include Nuvista Pharma Limited (NPL), Synovia Pharma PLC (SPP), Beximco Pharma API Limited (BPAL).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
122.4 BDT
Average target price
168.3 BDT
Spread / Average Target
+37.53%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BXPHARMA Stock
  4. News Beximco Pharmaceuticals Limited
  5. Beximco Lands Sub-License From United Nations-Backed Program For COVID-19 Treatment
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW